| Bid | 4.67 |
| Market Cap | 280.18M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -6.27 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.12 |
| Volume | 275,195 |
| Avg. Volume (20D) | 469,131 |
| Open | 4.80 |
| Previous Close | 4.77 |
| Day's Range | 4.67 - 4.87 |
| 52-Week Range | 2.71 - 6.55 |
| Beta | undefined |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria...
Analyst Forecast
According to 2 analyst ratings, the average rating for ALDX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 112.54% from the latest price.
2 months ago · seekingalpha.com
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's ProspectsAldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Al...
